Background: Kaposi’s sarcoma (KS) is a lymphangioproliferative tumour. Therapy of KS depends on the characteristics of the disease, especially area and growth rate of lesions, and patient condition. Currently symptomatic resectable lesions are excised, whereas more advanced disease and unresectable lesions are treated with radiotherapy. If a large area or internal organs are affected or other treatments fail, chemotherapy is used. Recently some authors have reported their encouraging experience in the use of thalidomide in patients with AIDS-related KS. Objective: To evaluate the efficacy of thalidomide in 3 patients with non-AIDS-related KS. Methods: Two patients with classic widespread cutaneous and 1 with iatrogenic cutaneous and visceral KS were treated with thalidomide (100 mg/day) for 12 months. Results: In all 3 patients partial remission was evident after 4 months of thalidomide therapy; in 2 out of 3 complete remission was achieved after 12 months of treatment. Conclusions: Our results seem to confirm the utility of thalidomide in the treatment of non-AIDS-related KS.

Keywords:
Kaposi’s sarcoma, Thalidomide
1.
Sanders C, Canninga-van Dijk M, Borleffs J: Kaposi’s sarcoma. Lancet 2004;364:1549–1552.
2.
Buonaguro FM, Tornesello ML, Buonaguro L, Satriano RA, Ruocco E, Castello G, Ruocco V: Kaposi’s sarcoma: aetiopathogenesis, histology and clinical features. J Eur Acad Dermatol Venereol 2003;17:138–154.
3.
Viejo-Borbolla A, Schultz TF: Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV8): key aspects of epidemiology and pathogenesis. AIDS Rev 2003;5:222–229.
4.
Cattelan AM, Trevenzoli M, Aversa SM: Recent advances in the treatment of AIDS-related Kaposi’s sarcoma. Am J Clin Dermatol 2002;3:451–462.
5.
Mendez JC, Procop GW, Espy MJ, Paya CV, Smith TF: Detection and semiquantitative analysis of human herpesvirus 8 DNA in specimens from patients with Kaposi’s sarcoma. J Clin Microbiol 1998;36:2220–2222.
6.
Kazakov DV, Schmid M, Adams V, Cathomas G, Muller B, Burg G, Kempf W: HHV-8 DNA sequences in the peripheral blood and skin lesions of an HIV-negative patient with multiple eruptive dermatofibromas: implications for the detection of HHV-8 as a diagnostic marker for Kaposi’s sarcoma. Dermatology 2003;206:217–221.
7.
Brambilla L, Labianca R, Ferrucci SM, Taglioni M, Boneschi V: Treatment of classical Kaposi’s sarcoma with gemcitabine. Dermatology 2001;202:119–122.
8.
Krown SE: Management of Kaposi sarcoma: the role of interferon and thalidomide. Curr Opin Oncol 2001;13:374–381.
9.
Soler RA, Howard M, Brink NS, Gibb D, Tedder RS, Nadal D: Regression of AIDS-related Kaposi’s sarcoma during therapy with thalidomide. Clin Infect Dis 1996;23:501–503.
10.
Krown SE: Therapy of AIDS-associated Kaposi’s sarcoma: targeting pathogenetic mechanism. Hematol Oncol Clin North Am 2003;17:763–783.
11.
Okafor MC: Thalidomide for erythema nodosum leprosum and other applications. Pharmacotherapy 2003;23:481–493.
12.
Wu JJ, Huang DB, Pang KR, Hsu S, Tyring SK: Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol 2005;153:254–273.
13.
Jacob SE, Fien S, Kerdel FA: Scleromyxedema, a positive effect with thalidomide. Dermatology 2006;213:150–152.
14.
Sander CS, Kaatz M, Elsner P: Successful treatment of cutaneous Langerhans cell histiocytosis with thalidomide. Dermatology 2004;208:149–152.
15.
Fife K, Howard MR, Gracie F, Phillips RH, Bower M: Activity of thalidomide in AIDS-related Kaposi’s sarcoma and correlation with HHV-8 titre. Int J STD AIDS 1998;9:751–755.
16.
Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, Newcomb FM, Tosato G, Feigal E, Steinberg SM, Whitby D, Goedert JJ, Yarchoan R: Activity of thalidomide in AIDS-related Kaposi’s sarcoma. J Clin Oncol 2000;18:2593–2602.
17.
D’Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082–4085.
18.
Lepper ER, Ng SS, Gutschow M, Weiss M, Hauschildt S, Hecker TK, Luzzio FA, Eger K, Figg WD: Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors. J Med Chem 2004;47:2219–2227.
19.
de Medeiros BC, Rezuke WN, Ricci A Jr, Tsongalis G, Shen PU, Bona RD, Feingold JM, Edwards RL, Tutschka PJ, Bilgrami S: Kaposi’s sarcoma following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia. Acta Haematol 2000;104:115–118.
20.
González-López MA, Rodrigo E, González-Vela MC, Fernández-Llaca H, Arias-Rodríguez MA, Val-Bernal JF: Posttransplant Kaposi’s sarcoma restricted to the site of a previous deep venous thrombosis: abrupt onset after withdrawal of sirolimus. Dermatology 2006;213:30–33.
21.
Milazzo L, Biasin M, Gatti N, Piacentini L, Niero F, Zanone Poma B, Galli M, Moroni M, Clerici M, Riva A: Thalidomide in the treatment of chronic hepatitis C unresponsive to α-interferon and ribavirin. Am J Gastroenterol 2006;101:399–402.
22.
Briani C, Zara G, Rondinone R, Della Libera S, Ermani M, Ruggero S, Ghirardello A, Zampieri S, Doria A: Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology 2004;62:2288–2290.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.